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Abstract
Cancer arising from the proximal biliary tree, or hilar cholangiocarcinoma, remains a difficult clinical problem. Significant
experience with these uncommon tumors has been limited to a small number of centers, which has greatly hindered progress.
Complete resection of hilar cholangiocarcinoma is the most effective and only potentially curative therapy, and it now clear
that concomitant hepatic resection is required in most cases. Simply stated, long-term survival is generally possible only with
an en bloc resection of the liver with the extrahepatic biliary apparatus, leaving behind a well perfused liver remnant with
adequate biliary-enteric drainage. Preoperative imaging studies should aim to assess this possibility and must evaluate a
number of tumor-related factors that influence resectability. Advances in imaging technology have improved patient selection,
but a large proportion of patients are found to have unresectable disease only at the time of exploration. Staging laparoscopy
and 13fluoro-deoxyglucose positron emission tomography (FDG-PET) may help to identify some patients with advanced
disease; however, local tumor extent, an equally critical determinant of resectability, may be underestimated on preoperative
studies. This paper reviews issues pertaining to diagnosis and preoperative evaluation of patients with hilar biliary obstruction.
Knowledge of the imaging features of hilar tumors, particularly as they pertain to resectability, is of obvious importance for
clinicians managing these patients.
Demographics
Biliary tract cancer affects approximately 7500 Amer-
icans each year. Tumors arising from the gallbladder
are the most common while those of bile duct origin are
less frequently encountered, constituting about 2% of
all reported cancers. The advent of new diagnostic
methods has led to the preoperative discovery of many
more of these lesions, almost certainly misdiagnosed in
the past. The majority of patients are greater than 65
years of age, and the peak incidence occurs in the
eighth decade of life.
Cholangiocarcinoma may arise anywhere within the
biliary tree but tumors involving the biliary confluence
(hilar cholangiocarcinoma) are the most common. In
several large series published over the past three
decades, the proportion of patients with hilar tumors
has remained fairly constant at 40–60%, with the
remainder arising from intrahepatic biliary radicles or
the distal bile duct.
The majority of patients with unresectable bile duct
cancer die within 12 months of diagnosis, often from
hepatic failure or infectious complications secondary to
biliary obstruction. The prognosis has been considered
worse for lesions involving the biliary confluence
compared with that for distal lesions. This probably
reflects differences in resectability and delay often
associated with initiating effective therapy for proximal
lesions rather than a difference in biologic behavior.
Indeed, the available data would suggest that location
within the biliary tree (proximal versus distal) does not
impact survival, provided that complete resection is
achieved [1].
Etiology
Most cases of cholangiocarcinoma are sporadic and the
etiology is unclear, especially in Western countries, but
several conditions confer an increased risk. Perhaps the
most common of these is primary sclerosing cholangitis
(PSC), an autoimmune disease characterized by
periductal inflammation, ultimately resulting in multi-
focal strictures of the intrahepatic and extrahepatic
bile ducts. Seventy to 80% of patients have associated
ulcerative colitis; by contrast only a minority of
those with ulcerative colitis develop PSC. The natural
history of PSC is variable, and the true incidence
of cholangiocarcinoma is unclear. In a series of 305
patients with long-term follow-up, 8% eventually
developed cancer [2]. By contrast, occult cholangio-
carcinoma has been reported in up to 40% of autopsy
specimens and up to 36% of liver explants from
patients with PSC. PSC patients appear to be at
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greater risk for multifocal disease that is not amenable
to resection and often have significant underlying
hepatic dysfunction that precludes major partial
hepatectomy. Distinguishing benign from malignant
strictures is particularly challenging in the setting
of PSC.
The increased risk of cholangiocarcinoma in patients
with congenital biliary cystic disease (choledochal
cysts, Caroli’s disease) is well described. Malignant
degeneration, uncommon in choledochal cysts excised
early in life, increases substantially (approximately
15–20%) in patients who are not treated until after the
age of 20 years or in those previously treated by cyst
drainage. The reason for the high incidence of cancer in
patients with cystic diseases is not clear but may be
related to an abnormal choledochopancreatic duct
junction, predisposing to reflux of pancreatic secretions
into the biliary tree, chronic inflammation and bacterial
contamination. A similar mechanism may also explain
the increased incidence of cholangiocarcinoma
after transduodenal sphincteroplasty. In a cohort of
119 patients subjected to this procedure for benign
conditions, Hakamada et al. found a 7.4% incidence
of cholangiocarcinoma over a period of 18 years [3].
There is also evidence to suggest that endoscopic
sphincterotomy confers a similar increased risk.
Hepatolithiasis, or recurrent pyogenic cholangio-
hepatitis, is prevalent in Japan and parts of Southeast
Asia and is thought to result from chronic portal
bacteremia and portal phlebitis, giving rise to intra-
hepatic pigment stone formation. Obstruction of
intrahepatic ducts leads to chronic, recurrent episodes
of cholangitis and stricture formation. Although sepsis
is the major threat to life in these patients, approxi-
mately 10% will develop cholangiocarcinoma. Biliary
parasites (Clonorchis sinensis, Opisthorchis viverrini), also
prevalent in parts of Asia, are similarly associated with
an increased risk of cholangiocarcinoma. In Thailand,
where approximately 7 million people are infested
with Opisthorchis, the annual incidence of cholangio-
carcinoma is 87 per 100 000.
Pathological considerations
Knowledge of some of the unique pathologic
features of hilar cholangiocarcinoma is important
when assessing patients for subsequent therapy. The
overwhelming majority are adenocarcinomas, although
rarely other malignant cell types may arise primarily
in the biliary tree (e.g. carcinoid tumors). It has
been suggested that the hilar cholangiocarcinoma is a
relatively slow-growing, predominantly locally invasive
tumor. However, metastatic disease is not uncommon
and disease progression can be rapid in some patients
[4]. The liver is a common site of metastasis, but
distant spread to other organs at initial presentation,
particularly extra-abdominal sites, is atypical. On
the other hand, nodal metastases are seen in up to
one-third of cases. Following a complete resection,
the impact of metastatic disease to hepatoduodenal
ligament lymph nodes is unclear, as not all studies have
uniformly found an adverse impact on outcome. By
contrast, metastatic spread to more distant nodal
basins, which can occur in the absence of more
proximate nodal involvement, is associated with
reduced survival.
By virtue of their location, hilar tumors often invade
the liver or perihepatic structures, such as the portal
vein or hepatic artery. Given this feature, along with
frequent tumor extension to second order biliary
radicles, it is not difficult to understand why hepatic
resection is usually required for complete tumor
clearance [5]. Additionally, concomitant involvement
of either the right or left portal vein often results
in lobar atrophy, which has important clinical impli-
cations, not only for operative planning but also
when considering biliary drainage in patients with
unresectable disease. Such vascular involvement
and lobar atrophy does not always translate into
irresectability but it mandates a concomitant partial
hepatectomy if resectable and suggests a more locally
advanced lesion with an apparent higher likelihood of
associated metastatic disease [4,5].
Other characteristics of cholangiocarcinoma include
invasive spread with neural, perineural and lymphatic
involvement and subepithelial extension. Longitudinal
spread along the duct wall and periductal tissues is an
important pathologic feature of cholangiocarcinomas.
There may be substantial extension of tumor beneath
an intact epithelial lining, as much as 2 cm proximally
and 1 cm distally. The full tumor extent may thus be
underestimated by radiographic studies and may not
be appreciated on palpation, underscoring the impor-
tance of frozen section analysis of the duct margins
during operation to ensure a complete resection.
Grossly, three macroscopic subtypes have been
described: sclerosing, nodular and papillary [6].
Sclerosing tumors, the most common, are very firm
and cause an annular thickening of the bile duct, often
with diffuse infiltration and fibrosis of the periductal
tissues. Nodular tumors are characterized by a firm,
irregular nodule of tumor that projects into the lumen
of the duct. Features of both types are often seen, hence
the frequently used descriptor ‘nodular-sclerosing’.
The papillary variant accounts for approximately 10%
of all cholangiocarcinomas, and while occasionally
seen at the hilus, is more common in the distal bile
duct. These tumors are soft and friable, and may be
associated with little transmural invasion. A polypoid
mass that expands rather than contracts the duct is a
characteristic feature. Although papillary tumors
may grow to significant size, they often arise from a
well-defined stalk and may be mobile within the bile
duct (Figure 1). Recognition of this variant is
important since they are more often resectable and
less invasive, although it remains to be determined if
they have a better prognosis.
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Clinical presentation
The early symptoms of hilar cholangiocarcinoma are
often non-specific. Abdominal pain or discomfort,
anorexia, weight loss and pruritus are the most
common but are seen only in about one-third of
patients. Most patients have few symptoms and come
to attention because of jaundice or abnormalities
on routine blood testing. Although most patients
eventually become jaundiced, this finding is not
present initially in cases of incomplete biliary obstruc-
tion (i.e. right or left hepatic duct). Unilateral
obstruction of the proximal right or left hepatic
duct may go unrecognized for months, resulting in
ipsilateral lobar atrophy without overt jaundice. These
patients are often further evaluated and found to have
an elevated alkaline phosphatase or gamma glutamyl-
transferase. In some patients, pruritus precedes
jaundice by some weeks, and this symptom should
prompt an evaluation, especially if associated with
abnormal liver function tests. Patients with papillary
tumors may give a history of intermittent jaundice,
likely resulting from loose fragments that detach from a
friable papillary tumor of the right or left hepatic duct
and pass into the common hepatic duct (Figure 1).
Alternatively, the main tumor itself, if mobile within
the lumen, may cause a ball-valve effect at the hepatic
duct confluence. In the absence of previous biliary
intervention, cholangitis is uncommon at initial
presentation, despite a 30% incidence of bacterial
contamination (bacterbilia). On the other hand, the
incidence of bacterbilia is nearly 100% after biliary
intubation, and cholangitis is more common [7].
The physical findings are often nonspecific but may
provide some useful information. Jaundice will usually
be obvious. Patients with pruritus often have multiple
excoriations of the skin. The liver may be enlarged and
firm as a result of biliary tract obstruction. The
gallbladder is usually decompressed and nonpalpable
with hilar obstruction. Thus, a palpable gallbladder
suggests a more distal obstruction or an alternative
diagnosis. Rarely, patients with long-standing biliary
obstruction and/or portal vein involvement may have
findings consistent with portal hypertension.
Diagnosis
The diagnosis of hilar cholangiocarcinoma is usually
made on evaluation of obstructive jaundice or elevated
liver enzymes. Although a small number of patients are
diagnosed before the serum bilirubin rises to clinically
apparent levels, progressive and unremitting jaundice
is the predominant clinical feature in most cases,
and diagnostic investigations are largely related to
elucidation of the cause of biliary tract obstruction.
Some patients will present with abdominal pain
mistakenly attributed to gallstone disease. It is impor-
tant to remember that gallstones or even common bile
duct stones may coexist with bile duct cancer.
However, in the absence of certain predisposing
conditions, choledocholithiasis infrequently causes
obstruction at the biliary confluence. It is therefore
imperative to fully investigate and delineate the level
and nature of any obstructing lesion causing jaundice
to avoid missing the diagnosis of carcinoma.
Most patients are referred after having had
some studies done elsewhere, usually a computed
tomography (CT) scan and some form of direct
cholangiography (PTC or ERCP). These studies are
often inadequate for full assessment of the tumor extent.
Many patients will have been surgically explored prior to
referral, often without reaching a definitive diagnosis. In
the absence of previous biliary tract surgery, the finding
of a focal stricture involving the proximal biliary tree
combined with the appropriate clinical presentation
are sufficient for a presumptive diagnosis of hilar
cholangiocarcinoma, which is correct in most instances.
In a patient with a potentially resectable lesion, histo-
logic confirmation of malignancy should not be
considered mandatory prior to exploration (see below).
Figure 1. (a) PTC image showing hilar biliary ductal obstruction with a large filling defect. Note that the duct is expanded rather than
contracted, characteristic of a papillary tumor. (b) Axial CT image showing a well-circumscribed tumor at the biliary confluence (arrows),
without apparent invasion of the underlying portal vein. (c) Low power, hematoxylin/eosin-stained section of the resected tumor showing
little invasion of the bile duct wall. Reprinted from Annals of Surgery 2005; 241: 703–14, Jarmagin WR et al. Copyright 2005, with permission
from Elsevier.
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Imaging studies
Imaging studies play a critical role in evaluating
patients with biliary obstruction and should be directed
at fully assessing the extent of disease with a view
towards possible resection. In patients with hilar
cholangiocarcinoma, evaluation must address four
critical components of resectability: (1) level and
extent of tumor within the biliary tree; (2) vascular
invasion; (3) hepatic lobar atrophy; (4) distant meta-
static disease. A combination of studies providing
complementary information is typically required to
fully assess disease extent. Previously, direct cholangio-
graphy and angiography were considered essential
studies; however, advances in imaging technology have
made it possible to obtain the same information
without the need for invasive procedures.
Because of its wide availability, CT is often one of the
first studies obtained in patients with suspected biliary
tract obstruction. A high-resolution, thin cut CT scan
can provide valuable information regarding the level and
cause of biliary obstruction and the presence of lobar
atrophy and metastatic disease, and can therefore help
guide the subsequent evaluation. Also, image interpre-
tation on a PACS (Picture Archive and Communication
System) workstation allows consecutive slices to be
viewed in cine mode in order to better visualize dilated
bile ducts coursing in different planes. In addition, CT
angiography has now evolved to the point that
assessment of the hilar vascular structures can be done
without the need for invasive, direct angiography.
Ultrasonography is frequently overlooked as a useful
investigative tool for hilar cholangiocarcinoma;
however, in experienced hands, this non-invasive study
will demonstrate the level and extent of biliary
involvement and also provide information regarding
tumor invasion of the periductal tissues. Furthermore,
duplex ultrasonography is a highly accurate predictor
of vascular involvement and resectability (Figure 2).
In patients with malignant hilar obstruction, Hann
et al. showed that ultrasonography with color spectral
Doppler technique was equivalent to angiography and
CT portography in diagnosing lobar atrophy, level of
biliary obstruction, hepatic parenchymal involvement,
and venous invasion [8]. Duplex ultrasonography is
particularly useful for assessing portal venous invasion.
In a series of 63 consecutive patients from the Memorial
Sloan-Kettering Cancer Center, duplex ultrasono-
graphy predicted portal vein involvement in 93% of the
cases with a specificity of 99% and a 97% positive
predictive value. In the same series angiography with
CT angio-portography had a 90% sensitivity, 99%
specificity and a 95% positive predictive value [9].
Cholangiography is essential for full clarification of
disease extent within the biliary tree, clearly critical for
surgical planning. Although endoscopic retrograde
cholangiography (ERC) may provide some helpful
information, percutaneous transhepatic cholangio-
graphy (PTC) displays the intrahepatic bile ducts more
reliably and is the preferred direct cholangiographic
study. More recently, however, magnetic resonance
cholangiopancreatography (MRCP) has emerged as a
powerful investigative tool. Several studies have demon-
strated the utility of MRCP in evaluating patients with
biliary obstruction. MRCP may not only identify the
tumor and the level of biliary obstruction but may also
reveal obstructed and isolated ducts not appreciated on
endoscopic or percutaneous studies. MRCP also pro-
vides information regarding the presence of metastases
and lobar atrophy (Figure 2) and, when combined with
MRangiography, canassess involvementofhilar vascular
structures [10,11]. Thus, a single imaging modality may
provide all of the necessary diagnostic information
that previously required multiple studies (Figure 3).
Furthermore, since MRCP does not require biliary
instrumentation, bacterbilia and its consequent potential
for greater perioperative morbidity may be avoided.
Lobar atrophy
Lobar atrophy is not uncommon in patients with hilar
cholangiocarcinoma, and its importance cannot be
overemphasized, since it often influences therapy [4].
Long-standing biliary obstruction alone may cause
Figure 2. (a) Axial MRCP image of a patient with hilar cholangiocarcinoma and left lobe atrophy. The bile ducts appear white in this image
(black arrow). The left liver is shrunken (white arrow), with crowding and dilatation of the bile ducts. (b) Ultrasound image showing the tumor
at the biliary confluence (arrow) with severe narrowing of the left portal vein.
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moderate atrophy, whereas concomitant portal venous
compromise induces rapid and severe atrophy of
the involved segments. On cross-sectional imaging,
atrophy is characterized by a small, often hypoperfused
lobe with crowding of the dilated intrahepatic ducts
(Figure 2). Lobar atrophy is most often associated with
portal venous involvement and generally mandates
hepatic resection, if the tumor is resectable. Atrophy
is equally important when planning biliary decom-
pression in patients who are not candidates for
resection. Drainage of an atrophic, essentially
nonfunctional lobe, whether surgical or radiological,
will not relieve jaundice and should be avoided unless it
is done to control biliary sepsis.
Alternative diagnoses
The vast majority of patients with hilar strictures and
jaundice have cholangiocarcinoma. However, alter-
native diagnoses are possible and can be expected in
10–15% of patients [12]. The most common of
these are gallbladder carcinoma, Mirizzi syndrome
and idiopathic benign focal stenosis (malignant
masquerade). A thickened, irregular and distended
gallbladder is typical of gallbladder cancer, which is
in contrast to a typically shrunken gallbladder seen
with hilar obstruction. Gallbladder carcinoma is also
suggested by infiltration into segment IV and V of the
liver, selective involvement of the right portal pedicle, or
obstruction of the common hepatic duct with occlusion
of the cystic duct. Mirizzi syndrome is a benign
condition resulting from a large gallstone impacted in
the neck of the gallbladder (Figure 4). The ensuing
pericholecystic and periductal inflammation and fibrosis
can obstruct the proximal bile duct, which is often
Figure 3. Axial MRCP image of a patient with hilar cholangiocarcinoma. Note that the bile ducts appear white in this image. The tumor in the
bile duct is shown, with evidence of portal vein involvement and atrophy of the anterior sector of the right liver (delineated by the two
unlabelled lines). An intrahepatic metastasis is also shown.
Figure 4. ERCP image of a patient with Mirizzi’s syndrome.
A gallstone is impacted in the neck of the gallbladder (arrow),
causing biliary obstruction.
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difficult to distinguish from a malignant cause; also, it
must be recognized that gallbladder cancer can coexist
with Mirizzi syndrome.
Benign focal strictures (malignant masquerade)
can occur at the hepatic duct confluence but are
uncommon. A smooth, tapered stricture on cholangio-
graphy suggests a benign stricture but this is by no
means diagnostic, and hilar cholangiocarcinoma
must remain the leading diagnosis until definitively
disproved. In most cases, this cannot be done without
exploration. In fact, the alternative conditions that one
may encounter are best assessed and treated at
operation. Relying on the results of percutaneous
needle biopsy or biliary brush cytology is dangerous,
since they are often misleading and the opportunity to
resect an early cancer may be missed. In the absence of
clear contraindications, exploration is indicated in all
patients with suspicious hilar lesions.
Preoperative evaluation, staging, assessment
of resectability
Evaluation of patients with hilar cholangiocarcinoma
is principally an assessment of resectability, since
resection is the only effective therapy. First and
foremost, the surgeon must assess the patient’s general
condition and fitness for a major operation that usually
includes partial hepatectomy. The presence of
significant comorbid conditions, chronic liver disease
and/or portal hypertension generally precludes
resection. In these patients, biliary drainage and
histological confirmation of the diagnosis are most
appropriate if non-operative treatment is anticipated
(i.e. chemotherapy, radiation therapy). Patients with
potentially resectable tumors occasionally present
with biliary tract sepsis, most commonly after prior
intubation of the biliary tree. These patients require
resuscitation and treatment of infection before surgery
can be considered; this often requires placement of
additional biliary catheters to drain contaminated,
isolated liver segments.
Currently, there is no clinical staging system
available that stratifies patients preoperatively into
subgroups based on potential for resection. The
modified Bismuth–Corlette classification [5] stratifies
patients based only on the extent of biliary involvement
by tumor, and the AJCC staging system is based largely
on pathological criteria and has little applicability for
preoperative staging. Neither is useful for predicting
resectability and survival. Recently, the authors have
proposed a preoperative staging system, using data
from preoperative imaging studies, based on local,
tumor-related factors that determine resectability:
biliary ductal involvement, vascular involvement and
lobar atrophy [4]. This clinical T-staging scheme
categorizes patients from least to most locally advanced
by taking into account all factors related to local tumor
extent and correlates closely with resectability and
survival (Table I). In an analysis of 225 patients with
hilar cholangiocarcinoma, resectability was nearly 60%
in T1 tumors, 31% in T2 tumors and 0% of T3 tumors
(Table II). Survival likewise decreased with increasing
clinical T stage. On the other hand, there was no
correlation with survival and stage based on the
AJCC classification. In addition, and perhaps more
importantly, the likelihood of distant metastatic disease
increased with more locally advanced lesions
(i.e. higher clinical T stage—see below).
Table I. Proposed clinical T-stage criteria for hilar cholangiocarcinoma
Clinical stage Criteria
T1 Tumor involving biliary confluence+/7 unilateral extension to secondary biliary radicles
T2 Tumor involving biliary confluence+/7 unilateral extension to secondary biliary radicles AND
ipsilateral portal vein involvement+/7 ipsilateral hepatic lobar atrophy
T3 Tumor involving biliary confluence+bilateral extension to secondary biliary radicles;
OR unilateral extension to secondary biliary radicles with contralateral portal vein involvement;
OR unilateral extension to secondary biliary radicles with contralateral hepatic lobar atrophy;
OR main portal vein involvement
Reprinted from ref. no. 4 by permission of the publisher.














1 87 73 (84%) 51 (59%) 38 33 2 18 (21%) 20 months
2 95 79 (83%) 29 (31%) 24 29 7 40 (43%) 13 months
3 37 8 (22%) 0 0 0 0 15 (41%) 8 months
Total 219 160 (71%) 80 (37%) 62 62 9 73 (33%) 16 months
Six patients had incomplete data and could not be accurately staged. The percentages indicate the proportion of patients within each stage
grouping or of the total number of patients. Metastatic disease refers to metastases to N2 level lymph nodes or to distant sites. Median survival
was calculated for all patients, including those who died perioperatively. Reprinted from ref. no. 4 by permission of the publisher.
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Long-term survival with hilar cholangiocarcinoma
depends critically on a complete resection with
histologically negative resection margins. Proper patient
selection requires high quality, complementary imaging
studies and careful consideration of all of the available
data. The authors’ criteria of unresectable disease are
outlined in Table III [4]. Distant metastatic disease,
advanced cirrhosis, bilateral tumor extension to second
order intrahepatic biliary radicles and encasement or
occlusion of the main portal vein clearly preclude
resection. In general, however, the individual
determinants of resectability must be considered within
the context of all findings, and in so doing, the
importance of portal vein involvement and liver atrophy
in relation to the extent of ductal cancer spread
becomes evident. Thus, ipsilateral involvement of
the portal vein and bile ducts may be amenable to
resection whereas contralateral involvement is usually
not. Likewise, ipsilateral lobar atrophy does not
preclude resection, whereas atrophy of the contralateral
lobe does.
While imaging studies will identify many patients
with unresectable disease, a significant proportion
are found to have unresectable disease only at the time
of laparotomy. As a result, staging laparoscopy has
been used increasingly to reduce the incidence of
unnecessary open explorations. In a recent analysis
of 56 patients with potentially resectable tumors
on radiologic grounds, laparoscopy identified
unresectable tumors in 14 (25%) [13]. The yield was
significantly higher for patients with more locally
advanced tumors (clinical T2/T3, as discussed above)
(12/33, 36%) compared to those with clinical T1
tumors (2/23, 9%), which is almost certainly related to
the higher incidence of metastatic disease in the former
group. Laparoscopy detected the majority of patients
with peritoneal or liver metastases, but failed to detect
most locally unresectable tumors. Laparoscopic
detection of irresectability based on vascular involve-
ment and biliary tumor extent is particularly difficult in
patients with biliary stents. Despite this limitation,
however, laparoscopic staging appears to have a role in
these patients.
FDG-PET scanning may be a useful adjunct to
standard imaging but has not been fully evaluated in
patients with hilar cholangiocarcinoma, although
the few existing reports have suggested a potential
role. In one of the larger series to date, Kluge et al.
evaluated 26 patients with proximal and distal tumors,
8 patients with benign strictures and 20 control
patients [14]. This study showed that FDG-PET
has excellent sensitivity (92.3%) and specificity
(92.9%) with respect to identifying the primary lesion,
identified distant metastatic disease in 7 of 10 patients
but was relatively ineffective for identifying regional
nodal disease (2/15). FDG-PET may thus be of
some value in distinguishing benign from malignant
strictures and may identify some patients with
metastatic disease not apparent on cross-sectional
imaging.
The role of preoperative biliary drainage in jaun-
diced patients remains controversial. In practice, most
patients undergo biliary drainage prior to referral for
resection, despite the lack of data showing a benefit. In
the authors’ experience, many patients are ineffectively
and/or inappropriately drained before referral, often
leading to complications that delay treatment. Clearly,
the presence of cholangitis mandates biliary decom-
pression but there is no proof that routine biliary
drainage in all patients facilitates resection or reduces
post-surgical morbidity. On the contrary, there is some
suggestion that biliary stents are associated with greater
postoperative infective complications [7]. Previous
studies investigating this issue have been criticized for
a number of flaws, and whether major hepatic resection
in the face of biliary obstruction is associated with a
greater risk of liver failure or other complications
remains an open question. Several centers, particularly
in Japan, have a fundamentally different view, taking a
very detailed approach to defining resectability based
on aggressive direct cholangiography of segmental
ducts, often with multiple drainage catheters, and
Table III. Criteria of unresectability
Patient factors
Medically unfit or otherwise unable to tolerate a major operation
Hepatic cirrhosis
Local tumor-related factors
Tumor extension to secondary biliary radicles bilaterally
Encasement or occlusion of the main portal vein proximal to its bifurcation
Atrophy of one hepatic lobe with contralateral portal vein branch encasement or occlusion
Atrophy of one hepatic lobe with contralateral tumor extension to secondary biliary radicles
Unilateral tumor extension to secondary biliary radicles with contralateral portal vein branch encasement or occlusion
Metastatic disease
Histologically proven metastases to lymph nodes beyond the hepatoduodenal ligament*
Lung, liver, or peritoneal metastases
*Metastatic disease to peripancreatic, periduodenal, celiac, superior mesenteric or posterior pancreaticoduodenal lymph nodes was
considered to represent disease not amenable to a potentially curative resection. By contrast, metastatic disease to cystic duct,
pericholedochal, hilar or portal lymph nodes (i.e. within the hepatoduodenal ligament) did not necessarily constitute unresectability.
Reprinted from ref. no. 4 by permission of publisher.
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cholangioscopy [15]. This approach may offer an
advantage with respect to improving resectability rates
but a clear-cut improvement in perioperative outcome
has not been definitively shown.
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